Scarica l'app Stockscreener
8.17
0.12%
-0.010
Dopo l'orario di chiusura:
8.32
0.15
+1.84%
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
ORIC Pharmaceuticals shares surge on potential data leak - MSN
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications - MSN
Squarepoint Ops LLC Invests $1.08 Million in Oric Pharmaceuticals, Inc. $ORIC - Defense World
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) surges as intriguing ESMO Asia data for Enozertinib prompts Wells Fargo to assign higher value - MSN
Will ORIC Pharmaceuticals Inc. stock benefit from green energy trendsWatch List & AI Optimized Trading Strategy Guides - Улправда
How ORIC Pharmaceuticals Inc. stock reacts to Fed rate cuts2025 Market WrapUp & Reliable Trade Execution Plans - Улправда
Market Overview: How ORIC Pharmaceuticals Inc. stock reacts to Fed rate cutsWatch List & Safe Entry Trade Reports - Улправда
Why ORIC Pharmaceuticals Inc. stock attracts global investorsM&A Rumor & Growth Focused Investment Plans - DonanımHaber
Is ORIC Pharmaceuticals Inc. stock a buy on dipsDollar Strength & Growth-Oriented Investment Plans - DonanımHaber
Why retail investors favor ORIC Pharmaceuticals Inc. stockMarket Activity Report & Weekly Stock Breakout Alerts - DonanımHaber
How ORIC Pharmaceuticals Inc. stock reacts to job market dataExit Point & High Yield Stock Recommendations - DonanımHaber
Will ORIC Pharmaceuticals Inc. stock benefit from infrastructure spendingDividend Hike & Free Technical Confirmation Trade Alerts - DonanımHaber
How strong is ORIC Pharmaceuticals Inc. stock revenue growth2025 Momentum Check & AI Powered Market Entry Ideas - Улправда
ORIC Pharmaceuticals Earnings Notes - Trefis
Oric Pharmaceuticals (NASDAQ:ORIC) Insider Pratik Multani Sells 10,720 Shares - MarketBeat
Dominic Piscitelli Sells 10,720 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) CEO Sells 33,374 Shares - MarketBeat
[Form 4] Oric Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Oric Pharmaceuticals Executives Conduct Stock Transactions - TradingView — Track All Markets
Oric Pharmaceuticals President and CEO Sells Shares - TradingView — Track All Markets
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 7.5%Here's What Happened - MarketBeat
CFO Piscitelli Files To Sell 10,720 Of Oric Pharmaceuticals Inc [ORIC] - TradingView — Track All Markets
ORIC Pharmaceuticals (ORIC) Surges as Intriguing ESMO Asia Data for Enozertinib Prompts Wells Fargo to Assign Higher Value - Insider Monkey
20 Stocks That Will Double in 2026 - Insider Monkey
Frazier Life Sciences Management L.P. Sells 344,859 Shares of Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals Advances Key Cancer Drug Toward Late-Stage Trials - AD HOC NEWS
Oric Pharmaceuticals, Inc. $ORIC Shares Sold by EcoR1 Capital LLC - MarketBeat
Alkeon Capital Management LLC Boosts Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Responsive Playbooks and the ORIC Inflection - Stock Traders Daily
Stempoint Capital LP Makes New Investment in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Dir Kunkel Acquires 10,000 Of Oric Pharmaceuticals Inc [ORIC] - TradingView — Track All Markets
Vivo Capital LLC Has $31.74 Million Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Resolute Capital Asset Partners LLC Invests $2.31 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Wells Fargo maintains ORIC Pharmaceuticals (ORIC) overweight recommendation - MSN
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpShould You Buy? - MarketBeat
ORIC Pharmaceuticals (ORIC) Sees Analyst Rating Update from Wells Fargo | ORIC Stock News - GuruFocus
Oric Pharmaceuticals' (ORIC) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Wedbush Reiterates 'Outperform' Rating for ORIC Pharmaceuticals - GuruFocus
Wells Fargo raises ORIC Pharmaceuticals stock price target on promising cancer drug data - Investing.com Canada
Oric Pharmaceuticals, Inc. Presents Enozertinib Program Update - TradingView
JPMorgan Chase & Co. Raises Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC Pharmaceuticals (ORIC) Showcases Promising Phase 1b Trial D - GuruFocus
Oric Pharmaceuticals presents data from enozertinib trial at ESMO Asia - MSN
Transcript : ORIC Pharmaceuticals, Inc.Special Call - marketscreener.com
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 - Sahm
Fund Flows: Will ORIC Pharmaceuticals Inc stock see PE expansionPortfolio Growth Summary & Growth Focused Investment Plans - moha.gov.vn
Head to Head Survey: Oric Pharmaceuticals (NASDAQ:ORIC) & LENZ Therapeutics (NASDAQ:LENZ) - Defense World
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 - The Manila Times
ORIC Pharmaceuticals (Nasdaq: ORIC) shares Phase 1b NSCLC data with 67% ORR - Stock Titan
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust ... - Bakersfield.com
Dir Kunkel Acquires 5,534 Of Oric Pharmaceuticals Inc [ORIC] - TradingView
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Oric Pharmaceuticals (ORIC) Reveals Promising Trial Results for Enozertinib - GuruFocus
Oric Pharmaceuticals (ORIC) Presents Promising Phase 1b Trial Re - GuruFocus
ORIC (Nasdaq: ORIC) shows 35% ORR, 100% DCR in Phase 1b HER2 NSCLC trial - Stock Titan
Is ORIC Pharmaceuticals Inc. (4TZ) stock attractive for growth funds2025 Trade Ideas & Daily Profit Focused Stock Screening - Newser
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC - GlobeNewswire
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):